| Literature DB >> 34970101 |
Elif Çalışkan1, Munise Nur Şahin1, Mahmut Alper Güldağ2.
Abstract
Williams Syndrome (WS) is a rare genetic multisystem disorder that occurs because of a deletion of approximately 25 genes in the 7q11.23 chromosome region. This causes dysmorphic facial appearances, multiple congenital cardiovascular defects, delayed motor skills, and abnormalities in connective tissues and the endocrine system. The patients are mostly diagnosed with mild to moderate mental retardation, however, they have a hyper sociable, socially dis-inhibited, and outgoing personality, empathetic behavior, and are highly talkative. Oxytocin (OT), a neuropeptide synthesized at the hypothalamus, plays an important role in cognition and behavior, and is thought to be affecting WS patients' attitudes at its different amounts. Oxytocin receptor gene (OXTR), on chromosome 3p25.3, is considered regulating oxytocin receptors, via which OT exerts its effect. WS is a crucial disorder to understand gene, hormone, brain, and behavior associations in terms of sociality and neuropsychiatric conditions. Alterations to the WS gene region offer an opportunity to deepen our understandings of autism spectrum disorder, schizophrenia, anxiety, or depression. We aim to systematically present the data available of OT/OXTR regulation and expression, and the evidence for whether these mechanisms are dysregulated in WS. These results are important, as they predict strong epigenetic control over social behavior by methylation, single nucleotide polymorphisms, and other alterations. The comparison and collaboration of these studies may help to establish a better treatment or management approach for patients with WS if backed up with future research.Entities:
Keywords: Williams syndrome; Williams-Beuren syndrome; epigenetic regulation; neuromodulation; oxytocin; oxytocin receptor; oxytocin receptor gene; sociality; sociobehavior
Mesh:
Substances:
Year: 2021 PMID: 34970101 PMCID: PMC8686774
Source DB: PubMed Journal: Yale J Biol Med ISSN: 0044-0086
Figure 1Oxytocin signaling cascades [44]. From the article “Oxytocin and Sensory Network Plasticity” by Pekarek et al. in Front Neurosci, 2020
Figure 2PRISMA study flow diagram
Figure 3Search strategies
Quality Analysis of Studies Using NIH Quality Assessment Tool for Case-Control Studies
|
|
|
|
| |
| Research question or aim clearly stated and appropriate | Yes | Yes | Yes | Yes |
| Study population specified and defined | Yes | Yes | Yes | Yes |
| Includes sample size justification | Not reported | Not reported | Not reported | Not reported |
| Control selected from the same or similar population | Yes | Yes | Yes | Yes |
| Definitions, inclusion and exclusion criteria, algorithms, or processes to identify or select cases and controls are valid, reliable, and implemented consistently. | Yes | Yes | Not reported | Yes |
| Cases clearly defined and differentiated from controls | Yes | Yes | Yes | Yes |
| If less than 100 percent of eligible cases and/or controls were selected for the study, cases and/or controls randomly selected from those eligible | Not reported | Not reported | Not reported | Not reported |
| Use of concurrent controls | Yes | Yes | Yes | Yes |
| Investigators can confirm that the exposure/risk occurred before the development of the condition or event that defined a participant as a case | Yes | Yes | Yes | Yes |
| The measures of exposure clearly defined are valid, reliable, and implemented consistently across all study participants | Yes | Yes | Yes | Yes |
| The assessors of exposure/risk are blinded to the case or control status of participants | Not reported | Not reported | Not reported | Not reported |
| Statistical analysis accurate | Yes | Yes | Yes | Yes |
| Quality rating (Good, Fair, and Poor) | Good | Good | Good | Good |
Risk of bias analysis using Clarity Group Risk of Bias Tool for Case-Control Studies by McMaster University
|
|
|
|
| |
| Can we be confident in the assessment of exposure? | Definitely yes | Definitely yes | Definitely yes | Definitely yes |
| Can we be confident that cases had developed the outcome of interest and controls had not? | Definitely yes | Definitely yes | Definitely yes | Definitely yes |
| Were the cases properly selected? | Definitely yes | Definitely yes | Probably yes | Definitely yes |
| Were the controls properly selected? | Definitely yes | Definitely yes | Probably yes | Probably yes |
| Were cases and controls matched according to important prognostic variables or was statistical adjustment carried out for those variables? | Definitely yes | Definitely yes | Definitely yes | Definitely yes |
| Overall | Low risk | Low risk | Low risk | Low risk |
An Overview of the Research Items
|
|
|
|
|
|
| Dai et al. | Case-control human trial by comparing cohorts. | -Basal OT levels are higher in WS. | -WS cohort = 13 individuals (7 females aged 22–42, and 6 males aged
19–38). | -The median basal OT level is 3-times higher in WS. |
| Kimura et al. | Case-control human trial by comparison of cohorts and existing data. | -Show irregular OXTR levels in WS. | 1. For gene expression analysis: | -WS patients showed significantly lower expression of OXTR. -No
significant correlation between the expression levels of OXTR and total
SRS-T scores. |
| Haas et al. | Case-control human trial with comparison to existing patient data. | -Show if the irregular expression of OXTR alters OT functioning in WS. | -WS Cohort = 8 patients (mean age = 4.87 years; standard deviation =
2.10). | -WS subjects exhibited greater expression of OXTR. |
| Nygaard et al. | Case-control animal trial by comparing cohorts. | -Compare blood OT levels of WS with the control group. | 1. The cohort for blood OT test: WS = 13 mice, TC = 11 WT male mice from
8 independent litters. | -No significant differences in OT levels between genotypes. |